ABSTRACT: Chordomas are rare bone tumors and treatment is commonly based on a combination of surgery and radiotherapy. There is no standard chemotherapy treatment for chordoma. The aim of this study was to determine the expression of cyclin-dependent kinase 4 (CDK4) in chordoma and its therapeutic implications. We evaluated CDK4 expression both in chordoma cell lines and in chordoma tissues. Also, we investigated the functional roles of CDK4 in chordoma cell growth and proliferation. Furthermore, the therapeutic implications of targeting CDK4 in chordoma were evaluated. We found CDK4 highly expressed in chordoma cell lines and in a majority (97.7%) of chordoma tissues. Higher CDK4 expression correlated with metastasis and recurrence of chordoma. Treatment of chordoma cells using CDK4 inhibitor palbociclib could efficiently inhibit chordoma cells growth and proliferation. These data demonstrate that targeting CDK4 may be useful as a novel strategy in the treatment of chordoma. ß
Chordoma is a rare bone tumor presumably arising from persistent notochordal remnants along vertebral bodies. 1 It accounts for 1-4% of all malignant bone tumors. 1 The standard treatment for chordomas is enbloc resection accompanied by radiotherapy. 1, 2 However, the critical anatomic location (spread along critical bony and neural structures) and the commonly large tumor size make clinical management of these patients difficult. 1, 3, 4 After surgery, chordoma relapses occur in up to 50% of patients and metastasis in up to 40%. 3 Moreover, there is still no efficient standard therapy for chordomas. The overall survival of patients with chordoma is 67.6% at 5 years, 39.9% at 10 years, and 13.1% at 20 years. 3, 4 Therefore, there is a strong unmet need for developing effective therapeutic strategies.
Uncontrolled cell proliferation and growth is a hallmark of cancer. 5 Cyclin-dependent kinases (CDKs) are members of the serine/threonine protein kinase family and play important roles in sarcoma cell cycle progression. 5 Among these kinases, CDK4 is a key regulator of cell cycle G1 phase progression and the G1-S transition. 6 Specifically, in response to proproliferative stimuli, cyclin D1 forms a complex with CDK4 and phosphorylates the retinoblastoma (Rb) protein, which inactivates the function of Rb. This relieves the Rb-mediated inhibition of the transcription factor E2F, which commits the cell to progression through the cell cycle. 6 CyclinD-CDK4 regulation is perturbed in a large proportion of human cancers, including sarcomas. Among 90 patients with enchondroma and chondrosarcoma, CDK4 expression was associated with high-grade chondrosarcoma both at mRNA and protein level. 7 Well-differentiated liposarcoma patients with local recurrence after tumor resection had a significantly higher CDK4 expression as compared with those patients without recurrence. 8 In rhabdomyosarcoma and Ewing sarcoma cell lines, knockdown of CDK4 abrogated cell proliferation and transformation via G1 phase cell cycle arrest. 9, 10 CDK4 thus appears to represent a potential therapeutic target for sarcoma patients.
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INK4A is one of the most frequently altered tumor suppressor genes in cancer, and p16
INK4A acts to restrict cell cycle progression by inhibiting CDK4 activity.
11 P16 INK4A deletion causes constitutive CDK4 activity, which leads to Rb hyperphosphorylation and aberrant regulation of the cell cycle. 12, 13 Cell cycle control in p16 INK4A -null but Rb-positive tumors can be efficiently inhibited by CDK4 inhibitors, such as palbociclib. 14, 15 In the majority of chordomas, the CDK inhibitor p16
INK4A gene is commonly deleted. Although previous studies have found that inhibition of CDK4 decreased cell viability and increased apoptosis in many types of cancers, the significance of CDK4 expression in chordoma is largely unknown.
Palbociclib is a highly selective CDK4/6 inhibitor. It arrests cells in G1 phase by blocking Rb phosphorylation at CDK4/6-specific sites. 16, 17 It is a well-tolerated drug with significant progression-free survival benefit in patients, in combination with letrozole, for the treatment of post-menopausal women with ER-positive, HER2-negative advanced breast cancer as initial therapy for their metastatic disease. 18, 19 Patients with other tumors, including sarcoma have been trialed with palbociclib as well. Therefore, in this study, we examined the expression of CDK4 in chordoma cell lines and tissue microarray (TMA). Subsequently, we investigated the functional role and potential mechanisms of CDK4 in the growth and proliferation of chordoma cells in vitro.
MATERIALS AND METHODS
Human Chordoma Cell Lines and Cell Culture
The UCH1 and UCH2 chordoma cell lines used in the study have been characterized and described in previous studies. [20] [21] [22] Mug-Chor1 was purchased from ATCC (American Type Culture Collection). CH22 is an established chordoma cell line in our laboratory. 23 These cell lines were cultured in mediums, DMEM (Life Technologies, Grand Island, NY) for UCH2 and CH22, RPMI1640 (Invitrogen, Carlsbad, CA) for UCH1 and Mug-Chor1, supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies). Cells were incubated at 37˚C in 5% CO 2 -95% air atmosphere and passaged when near-confluent monolayers were achieved using trypsin-EDTA solution.
Reagents
The highly selective inhibitor of CDK4/6, palbociclib (PD-0332991), was purchased from Selleck Chemicals (Houston, TX). Human nonspecific siRNA and CDK4 targeted siRNA (Genebank Accession Number: NM_000075.3) were purchased from Sigma-Aldrich (St. Louis, MO). Lipofectamine 1 RNAiMAX was purchased from Life Technologies. The monoclonal rabbit anti-human CDK4 antibody and the Rb pathway associated antibodies, including Rb and phospho-Rb, were purchased from Cell Signaling Technology (Danvers, MA).
Human Chordoma Tumor Tissue
Ten chordoma tissue samples were obtained from the Massachusetts General Hospital Sarcoma Tissue Bank and were used in accordance with the policies of the institutional review boards of the hospital (IRB protocol # 2007P-002464). Written informed consent was obtained from all patients whose specimens and clinical information were used for this research study. All tissue diagnoses were confirmed histologically, and proteins were extracted from these frozen tissues. The expression of CDK4/CDK6, p16
INK4A in these ten chordoma samples was determined by Western blot assay.
Tissue Microarray and Immunohistochemistry
A retrospective study of 85 samples (including local recurrent and metastasis) from 72 chordoma patients was identified for the TMA immunohistochemical staining as previously reported. 20 The expression level of CDK4 was determined based on the immunohistochemistry (IHC) protocol (paraffin) from Cell Signaling Technology (Beverly, MA). Briefly, 5-mmthick array sections were baked at 60˚C for 1 h, dewaxed with xylene (three times for 5 min each), rehydrated through 100% ethanol (twice for 5 min each), rehydrated through graded alcohol, and then immersed in deionized water for 10 min. Antigen retrieval was processed with Target Retrieval Solution (Dako, North America, Inc., Carpinteria, CA). After antigen retrieval, the slide was washed with PBS twice for 5 min. Following the process of antigen retrieval, endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide. After protein blocking with blocking solution for 1 h at room temperature, primary antibody (1:500 dilution, in 1% bovine serum albumin PBS) was applied at 4˚C overnight in a humidified chamber. Primary CDK4 antibody was probed at 4˚C overnight. Each step was succeeded by three Tri-buffered saline (TBS) rinses, and the bound antibody on the array was detected by using Signal- Immunostaining of the whole slide area was viewed and scored separately by three independent pathologists who were blinded to tumor characteristics and patients details of the samples. The immunostaining intensity pattern of CDK4 was assessed on a scale semi-quantitatively as follows: 0, no positive staining; 1, <10% positive cells; 2, 10-25% positive cells; 3, 26-50% positive cells; 4, 51-75% positive cells; 5, !76% positive cells. Tumors with a staining score of !3 were defined as high expression of CDK4 and <3 were defined as low expression.
MTT Assay
Cytotoxicity of palbociclib in chordoma cells was assessed by MTT (3(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay. Briefly, UCH2 or CH22 cells were seeded into 96-well culture plates at a density of 5 Â 10 3 cells per well. The cells were then treated with increasing concentrations of palbociclib for 5 days. Afterwards, 20 ml of MTT (5 mg/ml in PBS, purchased from Sigma-Aldrich) was added to each well and the plates were incubated for an additional 4 h. Finally, the resulting formazan product was dissolved with acid (HCl)-isopropanol and the absorbance at a wavelength of 490 nm was read on a SPECTRAmax Microplate Spectrophotometer from Molecular Devices (Sunnyvale, CA). Experiments were done in triplicate. Dose-response curves were fitted using GraphPad PRISM 5 software (GraphPad Software, La Jolla, CA).
Cell Counting
An inverse microscope coupled to a digital camera adapter was used. The pictures were uploaded in the UTHSCSA Image Tool Version 3.0 Final (http://compdent.uthscsa.edu/ dig/itdesc.html). The control and the treated cell lines were counted in six wells for calculation of the median with the SD.
Cell Migration Assay
Cell migration activity was detected by the wound healing assay. In brief, UCH2 and CH22 cells were seeded into sixwell plates at a density of 4 Â 10 5 cells per well and incubated overnight. Then the adherent cell layer was scraped in two parallel lines with a sterile 10 ml tip, and 60 nm of CDK4 specific siRNA was transfected into the cells immediately for an additional 36 h of starved incubation with low-serum medium containing 2% FBS. The wounds were photographed under a Nikon microscope (Diagnostic Instruments Inc.) equipped with a Zen Imaging software after 0, 16, and 32 h of CDK4 specific siRNA transfection. The wound width was evaluated by measuring the distance between the two edges of the scratch at five sites in each image. Cell migration distance was determined using the following formula: (wound width at the 0-h time point-wound width at the observed time point)/2. 680LT were purchased from LI-COR Biosciences (Lincoln, NE). Western blotting analyses were carried out as previously described. 17 Membrane signals were scanned using the Odyssey infrared imaging system and analyzed using Odyssey 3.0 software (LI-COR Biosciences). Relative expression values were normalized assigning the value of the cells in control groups to 1.0.
Western Blotting Analyses
Immunofluorescence Assay
The expression levels of CDK4 after transfection of CDK4 siRNA in chordoma cells were visualized by immunofluorescence assay. Forty-eight hours post transfection, cells were incubated in 4% paraformaldehyde, fixed in ice-cold methanol, and blocked with 1% bovine serum albumin (BSA). Immunostaining was performed using the CDK4 antibody and Alexa Fluor 594 conjugated goat anti-rabbit antibody (Life Technologies). Images were acquired by Nikon Eclipse Ti-U fluorescence microscope equipped with a SPOT RT TM digital camera. Green color represents CDK4 protein, and red color represents cytoplasm.
Flow Cytometry Analysis
After 48 h of treatment with palbociclib, UCH2 and CH22 cells were subjected to flow cytometry analysis to examine the cell cycle changes. The collected cells were fixed in 70% ethanol at 4˚C overnight, incubated in RNase A at 37˚C for 30 min, and dyed with probidium iodide for 30 min. The DNA content was determined by flow cytometry and the population of cells in each cell cycle phase was analyzed by the equipped MultiCycle software (Phoenix Flow Systems, San Diego, CA).
Statistical Analysis
GraphPad PRISM 5 software (GraphPad Software) was used to statistically analyze the data. Kaplan-Meier survival curves were generated to examine the relationship between the expression level of the CDK4 and patient survival rate. Survival time was calculated from the date of tumor diagnosis to the date of death or last follow-up. The differences between groups were evaluated using the unpaired Student's t-test. Errors were SD of averaged results, p values <0.05 were considered statistically significant between means, and p values <0.01 were accepted as a significant difference between means.
RESULTS
Expression of CDK4 in Chordoma Cell Lines and Chordoma Tumor Tissues
To explore the potential roles of CDK4 in human chordoma cell growth, we first determined the expression of CDK4 in human chordoma cell lines. As demonstrated by Western blot, CDK4 was constitutively expressed in UCH1, UCH2, Mug-Chor1, and CH22 cell lines, while no expression of p16 INK4A was detected in these cell lines (Fig. 1) . To preclude the possibility that CDK4 expression is an artefact induced by in vitro propagation, we also examined ( expression. Due to the structural similarity of CDK6 to CDK4 and Rb/pRb involvement in the CDK4/6 signaling pathway, we also determined the expressions of these proteins in the tested chordoma specimens and observed that most of the chordoma cell lines and tissues expressing CDK4 simultaneously expressed CDK6, Rb, and pRb.
Correlation Between CDK4 Expression and Clinicopathology CDK4 was highly expressed in chordoma cell lines and chordoma samples, implying that CDK4 may be associated with the development of chordoma. To further validate the clinical significance of CDK4 expression in patients with chordoma, we determined CDK4 levels in a human chordoma TMA by IHC, and evaluated the correlation between CDK4 expression and the pathological characteristics, as well as clinical prognosis of chordoma patients. CDK4 staining was detected in 85 TMA samples (including local recurrence or metastasis) from 72 patients ( Table 2 ). The patients' average age was 63.1 years (range: 19-85), and were predominantly male (69.4%). Of the 85 chordoma samples, two samples (2.35%) were classified as negative staining, 13 (15.29%) as score 1 staining, 27 (31.76%) as score 2 staining, 26 (30.59%) as score 3 staining, and 17 (20.0%) as score 4 staining. There were no samples with staining score 5. We evaluated the clinicopathologic features of the human tumor samples and found no significant relationship between CDK4 expression and age at surgery, gender, or tumor location (data not shown). There was statistical significance between the average CDK4 expression score for the local relapsed status (2.714) compared with the score for primary tumor (2.030, p ¼ 0.0050). The mean CDK4 expression score for the metastatic group (3.200) was significantly higher compared with the primary group (2.030, p ¼ 0.0012). Furthermore, the mean CDK4 expression score for the metastatic patients group (2.339) was significantly higher compared with the non-metastatic patients group (3.200, p ¼ 0.0086) (Fig. 2) .
The median overall survival for patients with low CDK4 expressing tumors was 136.4 months compared with 87.3 months for patients with high CDK4 expressing tumors. However, Kaplan-Meier survival analysis showed that the prognosis for chordoma patients did not achieve a statistically significant difference between the two groups (p ¼ 0.2131). The 5-year survival of the low CDK4 staining group and high CDK4 staining group was 69.89% and 63.85%, respectively. We further analyzed the correlation between expression of CDK4 and the prognosis of chordoma patients. The mean expression levels of CDK4 for survivors and non-survivors were 2.167 and 2.885, respectively, and a statistically significant difference was achieved between the two patients groups (p ¼ 0.0130) (Fig. 2) .
Effect of Palbociclib Treatment on Chordoma Cell Lines
After validating the expression and clinical significance of CDK4 in patients with chordoma, we further assessed the functional roles of CDK4 expression in chordoma cell proliferation and growth in vitro. As shown in Figure 3 , after exposure to increasing concentrations of palbociclib for 5 days, the cell viability was decreased in a dose-dependent manner in both UCH2 and CH22 cells, with the IC50 values for palbociclib at 0.1575 and 0.3929 mM, respectively. Furthermore, the inhibitory effect of palbociclib on the chordoma cell lines was confirmed by an alternative approach. The effect of a 5-day treatment with 0.01, 0.1, and 1.0 mM palbociclib on the growth of UCH2 and CH22 was analyzed by cell counting. The two chordoma cell lines responded to palbociclib with decreased cell numbers.
To investigate the alteration of the CDK4/6-Rb pathway following CDK4 inhibition, we determined the expression of several respective proteins after palbociclib treatment. As shown by the Western blot (Fig. 4) , after incubation of all cell lines with 0.1, 0.3, 1.0, and 3.0 mM palbociclib for 48 h, there was a strong decrease of pRb expression with increase of palbociclib concentration, whereas the upstream Rb expression was not significantly altered. To be noted, since palbociclib only inhibits CDK4/6 activity, but not the production, the Western blot showed that palbociclib had no influence on the expression of both CDK4 or CDK6.
CDK4 Silencing Suppressed the Phosphorylation of Rb and Cell Viability
To further validate the role of CDK4 in chordoma cell proliferation and growth, we knocked down CDK4 expression using CDK4 specific siRNA and investigated the alteration of chordoma cell viability and the CDK4/6-Rb pathway. The wound healing assay was performed in chordoma cells after CDK4 specific siRNA transfection. As illustrated in Supplementary Figure S1 , after 60 nM CDK4 specific siRNA transfection for 16 and 32 h, the cell migration activities were time-dependently repressed in both UCH2 and CH22 cells, as compared with the control groups (p < 0.01).
As showed by the MTT, after transfection with increasing concentrations of CDK4 siRNA for 3 days, the cell viability was dose-dependently inhibited in both UCH2 and CH22 cells, which was not observed in the nonspecific siRNA transfected cells (Supplementary Fig. S1 ). As shown in the Western blot (Fig. 4,  Supplementary Fig. S2 ), CDK4 siRNA transfection significantly inhibited CDK4 expression, whereas the expression of CDK6 was not influenced. Consistent with palbociclib treatment, CDK4 siRNA transfection inhibited the CDK4/6-Rb pathway in a dose-dependent manner, which demonstrated that pRb expression was decreased, whereas Rb expression was not dramatically altered. The effect of the knockdown was also confirmed by immunofluorescence assay (Supplementary Fig. S3 ).
CDK4 Inhibition Induced Human Chordoma Cell Cycle Arrest
To explore the underlying mechanisms that decrease chordoma cell proliferation and growth by CDK4 inhibition, we examined the changes to the cell cycle by flow cytometry after palbociclib treatment. Due to high concentrations of palbociclib resulting in pronounced cell death, we employed a compound dose of 1 mM for cell cycle determination. The cell cycle analysis showed that after 1 mM of palbociclib treatment for 24 h, a significant G1 cell cycle arrest accompanied by reductions in the fraction of cells in S phase were observed in both UCH2 and CH22 cells (Fig. 5) , suggesting that CDK4 inhibition was able to induce chordoma cell cycle arrest in G1 phase and inhibit DNA synthesis. We analyzed the cell cycle in triplicates.
DISCUSSION
In the current study, we found that all the tested chordoma cell lines were positive for CDK4 and negative for p16 INK4A protein. Though a previous study had analyzed 43 chordoma tissue sample for the expression of CDK4, they did not characterize the relationship between the expression level of CDK4 and the clinicopathological characteristics of chordoma. 24 Our TMA results showed that 97.7% of the chordoma tissue samples expressed CDK4 and 50.6% of the samples were classified as staining highly for CDK4. In our analyses, there was no correlation between CDK4 expression and age at surgery, gender, or tumor location. The mean CDK4 expression score in specimens from metastatic disease or recurrent status was significantly higher than those from primary specimens. Furthermore, previous studies have demonstrated a strong correlation between CDK4 expression and poor prognosis in different sarcomas, including liposarcoma, osteosarcoma, and others. [8] [9] [10] [11] 24, 25 In our study, the mean expression level of CDK4 for nonsurvivors was significantly higher than the survivors. ). 26, 27 The INK4 proteins inhibit cyclinD-CDK4 activity by directly binding to the CDK. 26, 27 Of the four INK4 proteins, p16
INK4A appears to be particularly important for tumor suppression. 28 Amplification of the genes encoding cyclin D1, CDK4, or deletion of the locus encoding p16
INK4A (also known as cyclin-dependent kinase inhibitor 2A [CDKN2A]) are major mechanisms by which the cyclinD-CDK4-INK4-Rb pathway can be activated. 27 In our previous study, we performed comparative genomic hybridization on 21 chordoma tumor samples and showed that loss of CDKN2A with or without loss of CDKN2B on 9p21.3 was observed in 80% of unique cases. 29 Then we expanded on the observations by analyzing 45 chordoma samples via high throughput genotyping of cancer-associated genes and found that nearly 86% of chordoma samples displayed copy loss at the locus for CDKN2A. 30 Here, we used 10 patient tumor samples and four chordoma cell lines to evaluate the expression patterns of p16 INK4A proteins and showed p16 INK4A was deficient in all the chordoma samples and in UCH1, UCH2, Mug-Chor1, and CH22 cell lines. Palbociclib is a specific inhibitor of CDK4/6. 31 In well-differentiated or dedifferentiated liposarcomas (WD/DDLS), more than 90% of patients have CDK4 amplification. Palbociclib was tested in CDK4-amplified WD/DDLS in a phase II study of the 200 mg dose. The results showed that progression-free survival was 66% at 12 weeks and the median progression-free survival was 18 weeks. 32 A follow-up phase II study of the 125 mg dose confirmed these results with a similar response rate and less toxic effects. 33 Palbociclib treatment of rhabdomyosarcoma cell lines caused G1 phase cell cycle arrest, prevented cell accumulation, and delayed growth of rhabdomyosarcoma xenografts in vivo. 9 For synovial sarcomas, palbociclib effectively inhibited pRb in three SyS cell lines (Yamato-SS, Aska-SS, and SYO-1), resulting in an induction of G1 arrest and proliferation block. 34 Here, we evaluated the effects of palbociclib in chordoma cell lines, including the novel chordoma cell line CH22 and confirmed that palbociclib could effectively inhibit chordoma cell growth and proliferation. The IC50 values for the UCH2 and CH22 were 0.1575 and 0.3929 mM, respectively. These results were similar to the IC50 values 24, 35 Furthermore, we investigated whether inhibition of the CDK4 pathway would result in decreased the pRb protein in the chordoma cell lines. First, we found that genetic knockdown of CDK4 by siRNA could only partly reduce the expression level of pRb. The pRb protein in chordoma cell lines was reduced and even disappeared in a dose-dependent manner after palbociclib treatment, but the Rb protein was not obviously change. Therefore, palbociclib did not alter the expression of CDK4 or upstream Rb but only their activity. The biochemical reagent acting on CDK4 inhibited the growth of the chordoma cell lines, suggesting that this inhibition is due to blocking the CDK4 pathway in these cells. 24 To elucidate the potential mechanism underlying chordoma cell growth decrease by CDK4 inhibition, flow cytometry analysis was used to determine cell cycle in UCH2 and CH22 cell lines after palbociclib treatment. The results showed that chordoma cells were significantly arrested in G1 phase of the cell cycle after palbociclib treatment. Hence, we noted that CDK4 inhibition by palbociclib decreased chordoma cell proliferation and growth through arresting the cell cycle in G1 phase.
As palbociclib did not result in a 100% of G1 arrest, combination therapy will be necessary to induce the effect, which may potentially translate into higher activity in the clinic. 34 The combination therapies can be investigated, including various chemotherapeutics, small molecule inhibitors, and targeted antibodies. 34 In conclusion, our study demonstrated that CDK4 is highly expressed in human chordoma tissues and cell lines, which correlated with some of the clinicopathological characteristics of chordoma patients. Inhibition of CDK4 by palbociclib decreased the chordoma cell growth and proliferation. These data suggest that CDK4 is a potential promising therapy target in the treatment of chordoma. Whether this effect can be enhanced by combination treatments deserves further preclinical investigations. 
